View Exam | PowerPak

1. All of the following are components of the Immune-Related Response Criteria EXCEPT:

A. Antitumor response based on total measurable tumor burden B. Percent changes in tumor burden per time point assessment C. Overall response derived from time point response assessment D. Quality of life changes per time point assessment

2. JT is a 50-year-old woman with unresectable stage III melanoma whose cancer has progressed after 4 months of therapy with dabrafenib + trametinib. Based on recent data, which of the following treatment would likely result in longest survival for JT?

A. Dacarbazine B. Pembrolizumab C. Ipilimumab D. Vemurafenib + trametinib

3. Although immunotherapies for melanoma share a spectrum of immune-related adverse events (AEs), which of the following AEs is common to ipilimumab, nivolumab and pembrolizumab?

A. Rash B. Gastrointestinal tract-related C. Infusion reaction D. Thyroid-related

4. Strategies to address the financial burden of cancer treatment include all of the following EXCEPT?

A. Eliminate low-value prescribing practices B. Mandate the use of Specialty Pharmacy C. Improve cost transparency D. Provide financial counseling as a part of cancer care

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following are components of the Immune-Related Response Criteria EXCEPT:

2. JT is a 50-year-old woman with unresectable stage III melanoma whose cancer has progressed after 4 months of therapy with dabrafenib + trametinib. Based on recent data, which of the following treatment would likely result in longest survival for JT?

3. Although immunotherapies for melanoma share a spectrum of immune-related adverse events (AEs), which of the following AEs is common to ipilimumab, nivolumab and pembrolizumab?

4. Strategies to address the financial burden of cancer treatment include all of the following EXCEPT?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following are components of the Immune-Related Response Criteria EXCEPT:

2. JT is a 50-year-old woman with unresectable stage III melanoma whose cancer has progressed after 4 months of therapy with dabrafenib + trametinib. Based on recent data, which of the following treatment would likely result in longest survival for JT?

3. Although immunotherapies for melanoma share a spectrum of immune-related adverse events (AEs), which of the following AEs is common to ipilimumab, nivolumab and pembrolizumab?

4. Strategies to address the financial burden of cancer treatment include all of the following EXCEPT?

« Return to Activity

Customers who Purchased
this Activity also Purchased